Arrowhead Pharmaceuticals (ARWR) Reaches New 52-Week High at $25.58
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $25.58 and last traded at $25.55, with a volume of 1500416 shares. The stock had previously closed at $24.41.
ARWR has been the topic of several analyst reports. Cantor Fitzgerald set a $24.00 price target on shares of Arrowhead Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, April 12th. BidaskClub raised shares of Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, February 14th. Chardan Capital reissued a “buy” rating and issued a $24.50 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, February 11th. B. Riley boosted their target price on shares of Arrowhead Pharmaceuticals from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, May 28th. Finally, TheStreet raised shares of Arrowhead Pharmaceuticals from a “d” rating to a “c+” rating in a research report on Thursday, May 30th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $24.86.
The firm has a market cap of $2.31 billion, a P/E ratio of -39.31 and a beta of 1.66.
In related news, General Counsel Patrick O’brien sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $24.88, for a total value of $746,400.00. Following the sale, the general counsel now directly owns 203,000 shares in the company, valued at approximately $5,050,640. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher Richard Anzalone sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $19.30, for a total transaction of $965,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 107,071 shares of company stock valued at $2,306,962. Company insiders own 4.80% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth approximately $52,000. First Quadrant L P CA raised its holdings in shares of Arrowhead Pharmaceuticals by 831.4% during the first quarter. First Quadrant L P CA now owns 3,353 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 2,993 shares during the period. Advisor Group Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 73.4% during the fourth quarter. Advisor Group Inc. now owns 8,670 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 3,670 shares during the period. Beaumont Financial Partners LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $124,000. Finally, LPL Financial LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $130,000. Institutional investors and hedge funds own 62.31% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Arrowhead Pharmaceuticals (ARWR) Reaches New 52-Week High at $25.58” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/arrowhead-pharmaceuticals-arwr-reaches-new-52-week-high-at-25-58/3031511.html.
About Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Further Reading: What is required to own or exchange cryptocurrency?
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.